Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel is supported with funding from Agios (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2019 | PNH treatment: ravulizumab vs. eculizumab

Anita Hill • 13 Jun 2019
EHA 2019
Non-Malignant Paroxysmal Nocturnal Hemoglobinuria Eculizumab Ravulizumab

Anita Hill, MBChB (Hons), MRCP, FRCPath, PhD, Leeds Teaching Hospital NHS Trust, Leeds, UK, discusses patient preferences for the treatment of their paroxysmal nocturnal hemoglobinuria (PNH). Dr Hill specifically mentions the results of a patient survey of ravulizumab (alxn1210) and eculizumab. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Anita Hill

Erythropoietin in AHA patients
1:25
Erythropoietin in AHA patients
Anita Hill • 13 Jun 2019
Treating Patients with PNH and AA
1:29
Treating Patients with PNH and AA
Anita Hill • 13 Jun 2019
Anita Hill: highlights from EHA 2019
2:05
Anita Hill: highlights from EHA 2019
Anita Hill • 13 Jun 2019
SAA treatment and QoL
1:50
SAA treatment and QoL
Anita Hill • 13 Jun 2019

Related Videos

Importance of long-term surveillance after gene therapy in patients with hemophilia
5:45
Importance of long-term surveillance after gene therapy in patients with hemophilia
Radek Kaczmarek • 20 Jul 2026
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
4:58
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
Radek Kaczmarek • 20 Jul 2026
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
5:18
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026
Understanding potential malignancy risk following AAV gene therapy in hemophilia
7:23
Understanding potential malignancy risk following AAV gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals